glp-1/gip receptor agonists New Weight-Loss Drugs Are Poised to Upend Preventive Cardiology Care in Patients With Obesity and Overweight Science Behind GLP 1 GIP

The researchers defined 16 GLP-1RA treatment scenarios for GLP-1RA users by semi-annually reassigning their treatment status, conditional on their current use status, thereby emulating dynamic treatment strategies over time

Retatrutide versus semaglutide versus tirzepatide: understanding why people search online The surge in online retatrutide searches is driven by clinical data that positions it as the most potent weight loss peptide in development

Rouette, J

GLP-1 Drugs: Effective Tools, But They Do Not Rebuild the Metabolic System GLP-1 receptor agonists reduce hunger, slow gastric emptying and improve blood sugar regulation

While clinical trials report gastrointestinal symptoms in 1544% of users, formally diagnosed gastroparesis appears uncommon

Semaglutide is a prescription-only drug, so advertising it directly to the public is very restricted